Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literaturearticle Published on 2021-12-022024-09-02 Journal: Frontiers in immunology [Category] 대상포진, [키워드] BAFF Belimumab immune-mediated necrotizing myopathy refractory IMNM rituximab SRP antibody [DOI] 10.3389/fimmu.2021.777502 PMC 바로가기 [Article Type] article
Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximabArticle Published on 2021-12-012023-06-11 Journal: Leukemia & lymphoma [Category] B형 간염, [키워드] anti-hepatitis B surface antibody Hepatitis B virus reactivation lymphoma rituximab [DOI] 10.1080/10428194.2021.1948034
Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab리툭시맙으로 치료받은 환자와 비교하여 인플릭시맙으로 치료받은 환자에서 COVID-19 발생률Article Published on 2021-12-012022-09-12 Journal: RMD Open [Category] SARS, 진단, [키워드] 95% CI adjusted Autoimmune disease clinical collected COVID-19 COVID-19 in patient COVID-19 infections COVID-19 pandemic COVID-19 symptom determine diagnose enrolled Epidemiology Evolution First wave Fisher form incidence incidence of COVID-19 incidence rate independent Inflammatory infliximab inhibitors Intensive life-threatening manifestation mechanical ventilation Patient patients treated patients with COVID-19 PCR-confirmed Quality receiving Replication reported symptom rituximab RTX self-reported symptom severe COVID-19 Symptom Symptoms the disease Therapies TNF treated treatment group tumour necrosis factor validation cohort while with COVID-19 [DOI] 10.1136/rmdopen-2021-001711 PMC 바로가기 [Article Type] Article
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study다발성 경화증에서 COVID-19 이후 체액성 면역 반응: 오스트리아 전국 연구Article Published on 2021-12-012022-09-11 Journal: Multiple sclerosis (Houndmills, Basingstoke, Engla [Category] SARS, 치료기술, [키워드] 95% CI 95% confidence interval age Analysis anti-CD20 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody Antibody testing COVID-19 disease-modifying treatment evaluate Evidence female humoral humoral immune response Humoral immunity Humoral response immune response Immunity immunomodulatory immunosuppressive median monoclonal antibodies Multiple multiple sclerosis Multivariate analysis Ocrelizumab Odds ratio Patient PCR-confirmed PCR-confirmed diagnosis positive PCR predictor Probability provide Rate reduced reduction regression models rituximab SARS-CoV-2 SARS-COV-2 infection Seropositivity significantly significantly lower symptomatic symptomatic COVID-19 Treatment vaccination was performed [DOI] 10.1177/13524585211049391 PMC 바로가기 [Article Type] Article
Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden스웨덴에서 다발성 경화증 환자의 COVID-19에 대한 리툭시맙 주입 시기, 누적 용량 및 입원Clinical Trial Published on 2021-12-012022-09-12 Journal: JAMA Network Open [Category] SARS, 임상, 진단, [키워드] case-control study COVID-19 COVID-19 infection individual infusion Multiple multiple sclerosis Person receiving risk rituximab sclerosis Severe COVID-19 Infection [DOI] 10.1001/jamanetworkopen.2021.36697 PMC 바로가기 [Article Type] Clinical Trial
SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine responseSARS CoV-2 백신 및 리툭시맙, 시기가 더 나은 백신 반응의 열쇠일 수 있음Article Published on 2021-12-012022-09-12 Journal: Joint bone spine [Category] SARS, 진단, [키워드] Abstract COVID rituximab SARS CoV-2 Vaccine vaccine response [DOI] 10.1016/j.jbspin.2021.105258 PMC 바로가기 [Article Type] Article
Undetectable SARS-CoV-2 active adaptive immunity-post-vaccination or post-COVID-19 severe disease-after immunosuppressants useSARS-CoV-2 능동 적응 면역-접종 후 또는 코로나19 이후 중증 질환-면역억제제 사용 후 검출 불가Case Reports Published on 2021-11-292022-09-11 Journal: BMJ case reports [Category] Coronavirus, SARS, 치료법, [키워드] acute respiratory distress acute respiratory distress syndrome adaptive Admission antibodies ARDS Care convalescent convalescent plasma COVID-19 COVID-19 pneumonia COVID-19 vaccination Dexamethasone died dissemination helping highlight IgG Immunity immunological immunological products and vaccines Immunosuppressant immunosuppressants Immunosuppressed immunosuppressed patient immunosuppressed patients Immunosuppression IMPROVE Infection infections Infectious diseases information malignant disease malignant disease and immunosuppression multiple sclerosis mycophenolate New nucleocapsid Ocrelizumab one patient Patient patients Pneumonia readmission Remdesivir renal reported required respiratory distress Respiratory distress syndrome Respiratory failure rituximab SARS-CoV-2 SARS-CoV-2 IgM secondary to Standard-of-care syndrome tacrolimus tested treated two patients ulcerative undetectable with COVID-19 worsening [DOI] 10.1136/bcr-2021-246308 PMC 바로가기 [Article Type] Case Reports
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia: A Comprehensive ReviewReview Published on 2021-11-192024-09-02 Journal: Cancers [Category] 대상포진, [키워드] AIHA CLL rituximab Steroids targeted drugs [DOI] 10.3390/cancers13225804 PMC 바로가기 [Article Type] Review
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis다발성 경화증에서 COVID-19 중증도와 질병 수정 요법의 연관성41 Published on 2021-11-092022-09-12 Journal: Neurology [Category] MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval Acetate adjusted adjusted odds ratio Admission admitted to ICU age Alemtuzumab analyzed artificial ventilation association Characteristics Cladribine Cohort coronavirus disease Coronavirus disease 2019 country covariate covariates COVID-19 COVID-19 cases COVID-19 severity cross-sectional design death demographic demonstrated died dimethyl fumarate disability EDSS EDSS score examined fumarate Glatiramer Glatiramer acetate higher risk Hospitalization Hospitalized ICU ICU admission immunosuppressive include increased risk indication intensive care intensive care unit interferon internal and external International Logistic regression Multiple multiple sclerosis Natalizumab objective Ocrelizumab Older age outcome outcomes Patient phenotype reflected required restriction Result risk factor rituximab scale sclerosis severe coronavirus disease severe COVID-19 severity Sex Siponimod status Stratification therapy Ventilation were assessed with COVID-19 [DOI] 10.1212/WNL.0000000000012753 PMC 바로가기 [Article Type] 41
470. Relapsing COVID-19 Pneumonia in Patients Receiving Rituximab TherapyPoster Abstracts Published on 2021-11-042022-10-29 Journal: Open Forum Infectious Diseases [Category] COVID-19, [키워드] acute respiratory syndrome administration anti-CD20 Antigen B-cell B-lymphocyte case sery CD20 clinical collected Controlled convalescent plasma Convalescent plasma therapy coronavirus disease Coronavirus-2 Corticosteroid Course COVID-19 COVID-19 diagnosis COVID-19 disease death discharge disease disease severity evaluate figure hospital IgG Infection initial management median median age monoclonal antibody Patient patient population patients positive Prevent receive receiving relapsing Remdesivir reported Result retrospective risk rituximab SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV2 severe COVID-19 severity of COVID-19 table therapy virus while [DOI] 10.1093/ofid/ofab466.669 PMC 바로가기 [Article Type] Poster Abstracts